Alzheimer’s Drugs Market Research Report: Market size, Industry outlook, Market Forecast, Demand Analysis,Market Share, Market Report 2018-2023
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Alzheimer’s Drugs Market
Alzheimer’s Drugs Market: By Phase (Phase-I, Phase-II, Phase-III and Others); By Drug Type (NMDA Receptor Antagonist, Acetylcholinesterase Inhibitor) and Geography - Forecast (2018-2023)
Report Code : HCR 0112
Updated Date: 11 May, 2018  

1. Alzheimer’s Drugs – Market Overview
2. Executive Summary
3. Alzheimer’s Drugs – Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Top 5 Financials Analysis
4. Alzheimer’s Drugs– Market Forces
   4.1. Market Drivers
      4.1.1. Growing prevalence of the neurological disorder in the geriatric population
      4.1.2. Increasing average life span of people
      4.1.3. Aging population
   4.2. Market Constraints
      4.2.1. Lack of techniques for diagnosing or treating Alzheimer’s disease
   4.3. Market Challenges
      4.3.1. Early Diagnosis of the Indication is Challenging
   4.4. Attractiveness of the Alzheimer’s Drugs Industry
      4.4.1. Power of Suppliers
      4.4.2. Power of Customers
      4.4.3. Threat of New Entrants
      4.4.4. Threat of Substitution
      4.4.5. Degree of Competition
5. Alzheimer’s Drugs Market – Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Alzheimer’s Drugs Market – By Drug Type
   6.1. NMDA Receptor Antagonist
   6.2. Acetylcholinesterase Inhibitor
7. Alzheimer’s Drugs Market – By Phase
   7.1. Phase-I
   7.2. Phase-II
   7.3. Phase-III and
   7.4. Others
8. Alzheimer’s Drugs Market - By Geography
   8.1. Introduction
   8.2. Global Study
   8.3. Americas
      8.3.1. North America
      8.3.2. Brazil
      8.3.3. Argentina
      8.3.4. Others
   8.4. Europe
      8.4.1. U.K.
      8.4.2. France
      8.4.3. Germany
      8.4.4. Others
   8.5. APAC
      8.5.1. China
      8.5.2. South Korea
      8.5.3. Japan
      8.5.4. India
      8.5.5. Others
   8.6. ROW
9. Alzheimer’s Drugs Market Market Entropy
   9.1. New Product Launches
   9.2. M&As, Collaborations, JVs and Partnerships
10. Company Profiles
   10.1. Roche
      10.1.1. Introduction
      10.1.2. Financials
      10.1.3. Key Insights
      10.1.4. Key Strategy
      10.1.5. Product Portfolio
      10.1.6. SWOT Analysis
   10.2. Genentech
      10.2.1. Introduction
      10.2.2. Financials
      10.2.3. Key Insights
      10.2.4. Key Strategy
      10.2.5. Product Portfolio
      10.2.6. SWOT Analysis
   10.3. Novartis
      10.3.1. Introduction
      10.3.2. Financials
      10.3.3. Key Insights
      10.3.4. Key Strategy
      10.3.5. Product Portfolio
      10.3.6. SWOT Analysis
   10.4. Eli Lilly
      10.4.1. Introduction
      10.4.2. Financials
      10.4.3. Key Insights
      10.4.4. Key Strategy
      10.4.5. Product Portfolio
      10.4.6. SWOT Analysis
   10.5. GE Healthcare
      10.5.1. Introduction
      10.5.2. Financials
      10.5.3. Key Insights
      10.5.4. Key Strategy
      10.5.5. Product Portfolio
      10.5.6. SWOT Analysis
   10.6. Eisai
      10.6.1. Introduction
      10.6.2. Financials
      10.6.3. Key Insights
      10.6.4. Key Strategy
      10.6.5. Product Portfolio
      10.6.6. SWOT Analysis
   10.7. Bayer Pharmaceuticals
      10.7.1. Introduction
      10.7.2. Financials
      10.7.3. Key Insights
      10.7.4. Key Strategy
      10.7.5. Product Portfolio
      10.7.6. SWOT Analysis
   10.8. Merck
      10.8.1. Introduction
      10.8.2. Financials
      10.8.3. Key Insights
      10.8.4. Key Strategy
      10.8.5. Product Portfolio
      10.8.6. SWOT Analysis
   10.9. Navidea
      10.9.1. Introduction
      10.9.2. Financials
      10.9.3. Key Insights
      10.9.4. Key Strategy
      10.9.5. Product Portfolio
      10.9.6. SWOT Analysis
   10.10. Diagenic
      10.10.1. Introduction
      10.10.2. Financials
      10.10.3. Key Insights
      10.10.4. Key Strategy
      10.10.5. Product Portfolio
      10.10.6. SWOT Analysis
*More than 10 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix

   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Bibliography
   11.5. Compilation of Expert Insights
   11.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll